Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Sep. 30, 2017 | Oct. 27, 2017 | |
Document And Entity Information [Abstract] | ||
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Sep. 30, 2017 | |
Document Fiscal Year Focus | 2,017 | |
Document Fiscal Period Focus | Q3 | |
Trading Symbol | CEMP | |
Entity Registrant Name | CEMPRA, INC. | |
Entity Central Index Key | 1,461,993 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Large Accelerated Filer | |
Entity Common Stock, Shares Outstanding | 52,512,385 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2017 | Dec. 31, 2016 |
Current assets | ||
Cash and equivalents | $ 176,134 | $ 231,553 |
Receivables | 2,803 | 6,162 |
Prepaid expenses | 833 | 579 |
Total current assets | 179,770 | 238,294 |
Furniture, fixtures and equipment, net | 27 | 48 |
Deposits | 83 | 173 |
Total assets | 179,880 | 238,515 |
Current liabilities | ||
Accounts payable | 6,665 | 15,657 |
Accrued expenses | 1,036 | 2,929 |
Accrued payroll and benefits | 1,286 | 4,267 |
Current portion of long-term debt | 6,667 | 6,667 |
Total current liabilities | 15,654 | 29,520 |
Deferred revenue | 16,987 | 16,987 |
Long-term debt | 3,682 | 8,660 |
Total liabilities | 36,323 | 55,167 |
Commitments and contingencies (Notes 4 and 8) | ||
Shareholders' Equity | ||
Preferred stock; $.001 par value; 5,000,000 shares authorized; no shares issued or outstanding at September 30, 2017 and December 31, 2016 | ||
Common stock; $.001 par value; 80,000,000 shares authorized; 52,509,281 and 52,392,905 issued and outstanding at September 30, 2017 and December 31, 2016, respectively | 53 | 52 |
Additional paid-in capital | 626,001 | 620,279 |
Accumulated deficit | (482,497) | (436,983) |
Total shareholders’ equity | 143,557 | 183,348 |
Total liabilities and shareholders’ equity | $ 179,880 | $ 238,515 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parenthetical) - $ / shares | Sep. 30, 2017 | Dec. 31, 2016 |
Statement Of Financial Position [Abstract] | ||
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 5,000,000 | 5,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, shares authorized | 80,000,000 | 80,000,000 |
Common stock, shares issued | 52,509,281 | 52,392,905 |
Common stock, shares outstanding | 52,509,281 | 52,392,905 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | |
Revenue | ||||
Contract research | $ 1,717 | $ 3,972 | $ 7,449 | $ 10,071 |
Total revenue | 1,717 | 3,972 | 7,449 | 10,071 |
Operating expenses | ||||
Research and development | 4,383 | 21,096 | 28,338 | 60,643 |
General and administrative | 7,867 | 15,021 | 21,291 | 35,333 |
Restructuring | 3,553 | |||
Total operating expenses | 12,250 | 36,117 | 53,182 | 95,976 |
Loss from operations | (10,533) | (32,145) | (45,733) | (85,905) |
Other income (expense) | ||||
Interest income | 382 | 128 | 896 | 330 |
Interest expense | (208) | (295) | (677) | (948) |
Other income (expense), net | 174 | (167) | 219 | (618) |
Net loss | $ (10,359) | $ (32,312) | $ (45,514) | $ (86,523) |
Basic and diluted net loss per share | $ (0.20) | $ (0.62) | $ (0.87) | $ (1.74) |
Basic and diluted weighted average shares outstanding | 52,508,598 | 52,072,536 | 52,470,568 | 49,616,785 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 9 Months Ended | |
Sep. 30, 2017 | Sep. 30, 2016 | |
Operating activities | ||
Net loss | $ (45,514) | $ (86,523) |
Adjustments to reconcile net loss to net cash used in operating activities | ||
Depreciation | 21 | 40 |
Share-based compensation | 5,464 | 7,518 |
Amortization of debt issuance costs | 22 | 44 |
Changes in operating assets and liabilities | ||
Receivables | 3,359 | 3,108 |
Prepaid expenses | (254) | (219) |
Deposits | 90 | (73) |
Accounts payable | (8,992) | 2,896 |
Accrued expenses | (1,893) | 615 |
Accrued payroll and benefits | (2,981) | 1,342 |
Net cash used in operating activities | (50,678) | (71,252) |
Investing activities | ||
Purchases of furniture, fixtures and equipment | (9) | |
Net cash used in investing activities | (9) | |
Financing activities | ||
Payment of long-term debt | (5,000) | (2,779) |
Proceeds from exercise of stock options | 259 | 364 |
Proceeds from issuance of common stock, net of underwriting discounts | 169,112 | |
Payment of offering costs | (284) | |
Net cash (used in) provided by financing activities | (4,741) | 166,413 |
Net change in cash and equivalents | (55,419) | 95,152 |
Cash and equivalents at beginning of the period | 231,553 | 153,765 |
Cash and equivalents at end of the period | 176,134 | 248,917 |
Supplemental cash flow information | ||
Cash paid for interest | $ 673 | $ 916 |
Description of Business
Description of Business | 9 Months Ended |
Sep. 30, 2017 | |
Organization Consolidation And Presentation Of Financial Statements [Abstract] | |
Description of Business | 1. Description of Business Cempra, Inc. (the “Company” or “Cempra”) is the successor entity of Cempra Pharmaceuticals, Inc. which was incorporated on November 18, 2005 and commenced operations in January 2006. Cempra is located in Chapel Hill, North Carolina, and is a pharmaceutical company focused on developing differentiated anti-infectives for acute care and community settings to meet critical medical needs in the treatment of infectious diseases. The Company expects to continue to incur losses and require additional financial resources to advance its products to either commercial stage or liquidity events. There can be no assurance that the Company will be able to obtain additional debt or equity financing or generate revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations and financial condition. In August 2017, the Company entered into an Agreement and Plan of Merger and Reorganization (“Merger Agreement”), with Melinta Therapeutics Inc. (“Melinta”). Under the terms of the Merger Agreement, shares of Melinta stock will be exchanged for Company shares whereby the current shareholders of Melinta will own approximately 52% of the Company’s stock after completion of the merger. The exchange ratio is subject to adjustment based upon the following; (1) the Company’s net cash balance at the closing of the transaction, (2) incremental debt incurred by Melinta before the close of the transaction, and (3) amount of transaction-related expenses incurred by Melinta. Consummation of the transaction is subject to certain closing conditions, including, among other things, approval by the stockholders of the Company of the transactions contemplated by the Merger Agreement and related matters. The Merger Agreement contains certain termination rights for both the Company and Melinta, and further provides that, upon termination of the Merger Agreement under specified circumstances, the Company may be required to pay Melinta a termination fee of $7.9 million and/or to reimburse certain expenses incurred by Melinta in an amount up to $2.0 million. The Company is expected to change its name to Melinta Therapeutics, Inc. and trade under the ticker symbol MLNT after the merger closes. |
Basis of Presentation
Basis of Presentation | 9 Months Ended |
Sep. 30, 2017 | |
Organization Consolidation And Presentation Of Financial Statements [Abstract] | |
Basis of Presentation | 2. Basis of Presentation Principles of Consolidation and Basis of Presentation The accompanying consolidated financial statements include the accounts and results of operations of Cempra and its wholly owned subsidiaries. The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany balances and transactions have been eliminated in consolidation. Unaudited Interim Financial Data The accompanying interim consolidated financial statements are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the accompanying notes for the year ended December 31, 2016 contained in the Company’s Annual Report on Form 10-K. The unaudited interim consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary for the fair statement of the Company’s financial position as of September 30, 2017 and the results of operations and cash flows for the three and nine-months ended September 30, 2017 and 2016. The December 31, 2016 consolidated balance sheet included herein was derived from audited consolidated financial statements, but does not include all disclosures including notes required by U.S. GAAP for complete financial statements. Use of Estimates The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Receivables Receivables consist of amounts billed and amounts earned but unbilled under the Company’s contract with the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services (“BARDA”). Receivables under the BARDA contract are recorded as qualifying research activities are conducted and invoices from the Company’s vendors are received. Unbilled receivables are also recorded based upon work estimated to be complete for which the Company has not received vendor invoices. The Company carries its accounts receivable less an allowance for doubtful accounts. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance based on its history of collections and write-offs and the current status of all receivables. The Company does not accrue interest on trade receivables. If accounts become uncollectible, they will be written off through a charge to the allowance for doubtful accounts. The Company has not recorded an allowance for doubtful accounts as management believes all receivables are fully collectible. Research and Development Expenses Research and development (“R&D”) expenses include direct and indirect R&D costs. Direct R&D consists principally of external costs, such as fees paid to investigators, consultants, central laboratories and clinical research organizations, including costs incurred in connection with clinical trials, and related clinical trial fees and all employee-related expenses for those employees working in research and development functions, including stock-based compensation for R&D personnel. Indirect R&D costs include insurance or other indirect costs related to the Company’s research and development function to specific product candidates. R&D costs are expensed as incurred. Expenses paid but not yet incurred are recorded in prepaid expenses. The Company expenses purchases of pre-approval inventory as R&D until regulatory approval is received. Clinical Trial Accruals As part of the process of preparing financial statements, the Company is required to estimate its expenses resulting from its obligation under contracts with vendors and consultants and clinical site agreements in connection with conducting clinical trials. The Company’s objective is to reflect the appropriate clinical trial expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. The Company determines accrual estimates through discussion with applicable personnel and outside service providers as to the progress of trials or the services completed. During the course of a clinical trial, the Company adjusts its rate of clinical trial expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known at that time. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. The Company’s clinical trial accrual is dependent upon the timely and accurate reporting of fee billings and passthrough expenses from contract research organizations and other third-party vendors as well as the timely processing of any change orders from the contract research organizations. Revenue Recognition The Company’s revenue generally consists of research related revenue under federal contracts and licensing revenue related to non-refundable upfront fees, milestone payments and royalties earned under license agreements. Revenue is recognized when the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products and/or services has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured. For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has “stand-alone value” to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling prices of each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods and services are delivered, limited to the consideration that is not contingent upon future deliverables. When an arrangement is accounted for as a single unit of accounting, the Company determines the period over which the performance obligations will be performed and revenue recognized. Milestone payments are recognized when earned, provided that (i) the milestone event is substantive; (ii) there is no ongoing performance obligation related to the achievement of the milestone earned; and (iii) it would result in additional payments. Milestone payments are considered substantive if all of the following conditions are met: the milestone payment is non-refundable; achievement of the milestone was not reasonably assured at the inception of the arrangement; substantive effort is involved to achieve the milestone; and the amount of the milestone appears reasonable in relation to the effort expended, the other milestones in the arrangement, and the related risk associated with the achievement of the milestone. Contingent-based payments the Company may receive under a license agreement will be recognized when received. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers. This new guidance clarifies the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP. The guidance outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes the most current revenue recognition guidance. This guidance, as amended by ASU 2015-14, is effective for fiscal years and interim periods within those years beginning after December 15, 2017, which is effective for the Company for the year ending December 31, 2018. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers: Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing, which clarifies an entity’s identification of its performance obligations in a contract. The update also clarifies the guidance regarding an entity’s evaluation of the nature of its promise to grant a license of intellectual property and whether or not that revenue is recognized over time or at a point in time. In May 2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients, which amends the guidance in the new revenue standard on collectability, non-cash consideration, presentation of sales tax, and transition. In December 2016, the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers which increases shareholders’ awareness of the proposals and expedites improvements to Update 2014-09. In September 2017, the FASB issued ASU 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842), which allows certain public business entities to elect to use the non-public business entities effective dates to adopt new standards on revenue (ASC 606) and leases (ASC 842). The amendments are intended to address implementation issues that were raised by stakeholders and provide additional practical expedients to reduce the cost and complexity of applying the new revenue standard. These pronouncements have the same effective date as the new revenue standard. The Company has evaluated the contract research agreement with BARDA, and does not anticipate a material impact on the financial statements. The Company is currently evaluating the license agreement with Toyama to determine the impact that the implementation of this standard will have on the financial statements, if any. The Company plans to use the full retrospective method of adoption effective January 1, 2018. In February 2016, the FASB issued ASU 2016-02, Leases. The new guidance will increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation. The new guidance simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The Company adopted this guidance as of January 1, 2017. As of December 31, 2016, the Company has accumulated excess tax benefits from temporary differences in the amount and timing of stock compensation expense and the Company’s deductions on its income tax return from the award compensation that reduces the net operating loss deferred tax asset. The Company provided a full valuation allowance against its net deferred tax assets since it has been determined that it is more likely than not that all of the deferred tax assets will not be realized. Upon implementation of this standard, the stock compensation excess tax benefit will be eliminated, resulting in an increase to the net operating loss deferred tax asset, with an increase in the valuation allowance of the same. The implementation of this standard has no impact on the Company’s consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. This new guidance is effective for fiscal years beginning after December 15, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements. In January 2017, the FASB issued ASU 2017-01, Business Combinations: Clarifying the Definition of a Business which revises the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This new guidance is effective for fiscal years beginning after December 15, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements. In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation. This new guidance provides clarity and reduces both diversity and complexity to the terms or conditions of a share-based payment award. This new guidance is effective for fiscal years beginning after December 15, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements. |
Fair Value of Financial Instrum
Fair Value of Financial Instruments | 9 Months Ended |
Sep. 30, 2017 | |
Fair Value Disclosures [Abstract] | |
Fair Value of Financial Instruments | 3. Fair Value of Financial Instruments The carrying values of cash and equivalents, receivables, prepaid expenses, and accounts payable at September 30, 2017 approximated their fair values due to the short-term nature of these items. The Company’s valuation of financial instruments is based on a three-tiered approach, which requires that fair value measurements be classified and disclosed in one of three tiers. These tiers are: Level 1, defined as quoted prices in active markets for identical assets or liabilities; Level 2, defined as valuations based on observable inputs other than those included in Level 1, such as quoted prices for similar assets and liabilities in active markets, or other inputs that are observable or can be corroborated by observable input data; and Level 3, defined as valuations based on unobservable inputs reflecting the Company’s own assumptions, consistent with reasonably available assumptions made by other market participants. At September 30, 2017 and December 31, 2016, the Company held money market funds classified as Level 1 financial instruments of $173.0 |
Significant Agreements and Cont
Significant Agreements and Contracts | 9 Months Ended |
Sep. 30, 2017 | |
Significant Agreements And Contracts [Abstract] | |
Significant Agreements and Contracts | 4. Significant Agreements and Contracts License Agreements Optimer Pharmaceuticals, Inc. In March 2006, the Company, through its wholly owned subsidiary, Cempra Pharmaceuticals, Inc., entered into a Collaborative Research and Development and License Agreement (“Optimer Agreement”) with Optimer Pharmaceuticals, Inc. (“Optimer”) which was acquired by Cubist Pharmaceuticals, Inc. in October 2013, which was in turn acquired by Merck in January 2015. Under the terms of the Optimer Agreement, the Company acquired exclusive rights to further develop and commercialize certain Optimer technology worldwide, excluding member nations of the Association of Southeast Asian Nations (“ASEAN”). In exchange for this license, during 2006 and 2007, the Company issued an aggregate of 125,646 common shares with a total fair value of $0.2 million to Optimer. These issuances to Optimer were expensed as incurred in research and development expense. In July 2010, the Company paid a $0.5 million milestone payment to Optimer after the successful completion of its first solithromycin Phase 1 program. In July 2012, the Company paid a $1.0 million milestone after the successful completion of its first solithromycin Phase 2 program. Both milestones were expensed as incurred in research and development expense. Under the terms of the Optimer Agreement, the Company will owe Optimer additional payments, contingent upon the achievement of various development, regulatory and commercialization milestone events. One such milestone event would be owed upon FDA approval of solithromycin which would result in a payment to Optimer of $9.5 million. The aggregate amount of such milestone payments the Company may need to pay is based in part on the number of products developed under the agreement and would total $27.5 million (including the two milestone payments made to date and the milestone payment for FDA approval) if four products are developed and gain FDA approval. The Company will also pay tiered mid-single-digit royalties based on the amount of annual net sales of its approved products. The Scripps Research Institute In June 2012, the Company entered into a license agreement with The Scripps Research Institute (“TSRI”), whereby TSRI licensed to the Company rights, with rights of sublicense, to make, use, sell, and import products for human or animal therapeutic use that use or incorporate one or more macrolides as an active pharmaceutical ingredient (“API”) and is covered by certain patent rights owned by TSRI claiming technology related to copper-catalysed ligation of azides and acetylenes. The rights licensed to the Company are exclusive as to the People’s Republic of China (excluding Hong Kong), South Korea and Australia, and are non-exclusive in all other countries worldwide, except ASEAN member-nations, which are not included in the territory of the license. Under the terms of the agreement with TSRI, the Company paid a one-time only, non-refundable license issue fee in the amount of $0.4 million which was charged to research and development expense in the second quarter of 2012. The Company is also obligated to pay annual maintenance fees to TSRI in the amount of (i) $50,000 each year for the first three years (beginning on the first anniversary of the agreement), and (ii) $85,000 each year thereafter (beginning on the fourth anniversary of the agreement). Each calendar year’s annual maintenance fees will be credited against sales royalties due under the agreement for such calendar year. Under the terms of the agreement, the Company must pay TSRI low single-digit percentage royalties on the net sales of the products covered by the TSRI patents for the life of the TSRI patents, a low single-digit percentage of non-royalty sublicensing revenue received with respect to countries in the nonexclusive territory and a mid-single-digit percentage of sublicensing revenue received with respect to countries in the exclusive territory, with the sublicensing revenue royalty in the exclusive territory and the sales royalties subject to certain reductions under certain circumstances. TSRI is eligible to receive milestone payments of up to $1.1 million with respect to regulatory approval in the exclusive territory and first commercial sale, in each of the exclusive territory and nonexclusive territory, of the first licensed product to achieve those milestones that is based upon each macrolide covered by the licensed patents. Each milestone is payable once per each macrolide. Each milestone payment made to TSRI with respect to a particular milestone will be creditable against any payment due to TSRI with respect to any sublicense revenues received in connection with the achievement of such milestone. Pursuant to the terms of the Optimer Agreement, any payments made to TSRI under this license for territories subject to the Optimer Agreement can be deducted from any sales-based royalty payments due under the Optimer Agreement up to a certain percentage reduction of the royalties due to Optimer. Under the terms of the agreement, the Company is also required to pay additional fees on royalties, sublicensing and milestone payments if the Company, an affiliate with the Company, or a sub licensee challenges the validity or enforceability of any of the patents licensed under the agreement. Such increased payments would be required until all patent claims subject to challenge are invalidated in the particular country where such challenge was mounted. In December 2014, the Company paid a $0.2 million milestone payment to TSRI in relation to license and milestone payments received under the license agreement with Toyama (discussed below). The term of the license agreement (and the period during which the Company must pay royalties to TSRI in a particular country for a particular product) will end, on a country-by-country and product-by-product basis, at such time as no patent rights licensed from TSRI cover a particular product in the particular country. TSRI may terminate the agreement in the event (i) the Company fails to cure any non-payment or default on its indemnity or insurance obligations, (ii) the Company declares insolvency or bankruptcy, (iii) the Company is convicted of a felony relating to the development, manufacture, use, marketing, distribution or sale of any products licensed under the agreement, (iv) the Company fails to cure any underreporting or underpayment by a certain amount in any 12-month period, or (v) the Company fails to cure any default on any other obligation under the agreement. The Company may terminate the agreement with or without cause upon written notice. In the event of such termination, (i) all licenses granted to the Company will terminate except in the case of any sublicensee that was not the cause of the termination, is not in default on its obligations under its sublicense, and that pays any unpaid amounts owed by the Company under the agreement with respect to the sublicense, and (ii) the Company may complete any work in progress and sell any completed inventory on hand for a period of time after termination. Biomedical Advanced Research and Development Authority In May 2013, the Company entered into an agreement with BARDA, for the evaluation and development of the Company’s lead product candidate solithromycin for the treatment of bacterial infections in pediatric populations and infections caused by bioterror threat pathogens. The agreement is a cost plus fixed fee development contract, with a base performance segment valued at approximately $18.7 million with contract modifications, and four option work segments that BARDA may request at its sole discretion pursuant to the agreement. If all four option segments are requested, the cumulative value of the agreement, as amended to date, would be approximately $68.2 million and the estimated period of performance would be until approximately May 2018. Three of the options are cost plus fixed fee arrangements and one option is a cost sharing arrangement without fixed fee, for which the Company is responsible for a designated portion of the costs associated with that work segment. The period of performance for the base performance segment was May 2013 through February 2016. BARDA exercised the second option in November 2014. The value of the second option work segment is approximately $16.0 million and the estimated period of performance is November 2014 through September 2018, which was extended in October 2017 at the Company’s request to allow more time to deliver the completed work product. This extension will not increase the cost of the work to be performed under the option nor does it change any other terms or provisions of the BARDA contract, including timeframes for other work options. In February 2016, BARDA exercised the third option work segment of the agreement which is intended to fund a Phase 2/3 study of intravenous, oral capsule and oral suspension formulations of solithromycin in pediatric patients from newborn to 17 years with community acquired bacterial pneumonia. This option work segment is a cost-sharing arrangement under which BARDA will contribute $25.5 million and the Company will be responsible for an additional designated portion of the costs associated with the work segment. In September 2016, the contract was modified to increase the third option work segment by $8.0 million for increased manufacturing work related to the development of a second supply source for solithromycin. The amendment raises the value of the third option work segment to approximately $33.5 million. The estimated period of performance of this option work segment runs through May 2018. Under the agreement, the Company is reimbursed and recognizes revenue as allowable costs are incurred plus a portion of the fixed-fee earned. The Company considers fixed-fees under cost reimbursable agreements to be earned in proportion to the allowable costs incurred in performance of the work as compared to total estimated agreement costs, with such costs incurred representing a reasonable measurement of the proportional performance of the work completed. Since inception of the agreement through September 30, 2017, the Company has recognized $46.7 million in revenue under this agreement. The agreement provides the U.S. government the ability to terminate the agreement for convenience or to terminate for default if the Company fails to meet its obligations as set forth in the statement of work. The Company believes that if the government were to terminate the agreement for convenience, the costs incurred through the effective date of such termination and any settlement costs resulting from such termination would be allowable costs. Any of the funding sources may request reimbursement for expenses or return of funds, or both, as a result of noncompliance by the Company with the terms of the grant. No reimbursement of expenses or return of funds for noncompliance has been requested or made since inception of the contract. Toyama Chemical Co., Ltd. In May 2013, Cempra Pharmaceuticals, Inc., the Company’s wholly owned subsidiary, entered into a license agreement with Toyama Chemical Co., Ltd. (“Toyama”), whereby the Company licensed to Toyama the exclusive right, with the right to sublicense, to make, use and sell any product in Japan that incorporates solithromycin, the Company’s lead compound, as its sole API for human therapeutic uses, other than for ophthalmic indications or any condition, disease or affliction of the ophthalmic tissues. Toyama also has a nonexclusive license in Japan and certain other countries, with the right to sublicense, to manufacture or have manufactured API for solithromycin for use in manufacturing such products, subject to limitations and obligations of the concurrently executed supply agreement discussed below. Toyama granted the Company certain rights to intellectual property generated by Toyama under the license agreement with respect to solithromycin or licensed products for use with such products outside Japan or with other solithromycin-based products inside or outside Japan. Following execution of the agreement, the Company received a $10.0 million upfront payment from Toyama. Toyama is also obligated to pay the Company up to an aggregate of $60.0 million in milestone payments, depending on the achievement of various regulatory, patent, development and commercial milestones. Under the terms of the license agreement, Toyama must also pay the Company a royalty equal to a low-to-high first double decimal digit percentage of net sales, subject to downward adjustment in certain circumstances. In August 2014, the Company received a $10.0 million milestone payment from Toyama (“August 2014 Milestone”), which was triggered by Toyama’s progress of its solithromycin clinical development program in Japan. The payment was made following Toyama’s receipt of regulatory acceptance to begin a Phase 2 trial of solithromycin in Japan following successful completion of a Phase 1 trial. In March 2015, the Company recognized a $10.0 million milestone from Toyama (“March 2015 Milestone”) based on the Japan Patent Office issuing a Decision of Allowance for the Company’s patent covering certain crystal forms of solithromycin in Japan, which payment was received in April 2015. In October 2016, the Company received the third $10.0 million milestone from Toyama (“October 2016 Milestone”), which was triggered by Toyama’s progress of the solithromycin clinical development program in Japan. As part of the license agreement, Toyama and the Company also entered into a supply agreement, whereby the Company will be the exclusive supplier (with certain limitations) to Toyama and its sublicensees of API for solithromycin for use in licensed products in Japan, as well as the exclusive supplier to Toyama and its sublicensees of finished forms of solithromycin to be used in Phase 1 and Phase 2 clinical trials in Japan. Pursuant to the supply agreement, which is an exhibit to the license agreement, Toyama will pay the Company for such clinical supply of finished product and all supplies of API for solithromycin for any purpose, other than the manufacture of products for commercial sale in Japan, at prices equal to the Company’s cost . The Company has determined that there are six deliverables under this agreement including (1) the license to develop and commercialize solithromycin in Japan, (2) the obligation of the Company to conduct Phase 3 studies and obtain regulatory approval in the United States and one other territory, (3) participation in a Joint Development Committee (“JDC”), (4) participation in a Joint Commercialization Committee (“JCC”), (5) the right to use the Company’s trademark, and (6) a supply agreement. The amounts received under the license agreement have been allocated to the deliverables based on their relative fair values and will be recognized into income when the revenue recognition criteria have been achieved. Milestone payments are recognized when earned, provided that (i) the milestone event is substantive; (ii) there is no ongoing performance obligation related to the achievement of the milestone earned; and (iii) it would result in additional payments. Milestone payments are considered substantive if all of the following conditions are met: the milestone payment is non-refundable; achievement of the milestone was not reasonably assured at the inception of the arrangement; substantive effort is involved to achieve the milestone; and the amount of the milestone appears reasonable in relation to the effort expended, the other milestones in the arrangement, and the related risk associated with the achievement of the milestone. Contingent-based payments the Company may receive under a license agreement will be recognized when received. Royalties are recorded as earned in accordance with the contract terms when third party sales can be reliably measured and collectability is reasonably assured. The Company recognized $4.3 million in revenue associated with the delivery of the license in May 2013. Additionally, because the milestone event triggering the August 2014 Milestone and October 2016 Milestone payments were considered non-substantive for accounting purposes, these milestone payments are being recognized into revenue proportionately to the six deliverables in the agreement using the same allocation as the upfront payment. Therefore, $4.3 million of the August 2014 Milestone payment was recognized into revenue in August 2014 and $4.3 million of the October 2016 Milestone payment was recognized into revenue in October 2016. The remainder of the upfront and milestone payments which aggregate to $17.0 million are recorded as deferred revenue at September 2017 and will be recognized as revenue when the revenue recognition criteria of each deliverable has been met. The Company also recognized in March 2015 a $10.0 million milestone based on the Japan Patent Office issuing a Decision of Allowance for the Company’s patent covering certain crystal forms of solithromycin in Japan. FUJIFILM Finechemicals Co., Ltd . In January 2016, Cempra Pharmaceuticals, Inc. entered into an API manufacturing and supply agreement with FUJIFILM Finechemicals Co., Ltd. (“FFFC”), which will provide the Company with solithromycin in sufficient quantities and at reasonable prices to help ensure it meets its obligation under the May 2013 supply agreement with Toyama. The Company will use reasonable efforts to ensure that the solithromycin supplied by FFFC is for use as the active pharmaceutical ingredient in a human drug product to be used or sold in Japan. The Company is subject to a minimum purchase obligation for a designated number of years after the successful completion of the manufacturing facility and validation studies by FFFC. Each calendar month, the Company will submit to FFFC a projection of the anticipated volume of solithromycin that it will order for the next designated period (as set forth in the agreement) (or, if earlier, the final calendar month of the current term). Several months of each forecast are binding and the remaining months are non-binding, provided that the quantity of solithromycin ordered for any month is between designated percentages of the quantity specified in the initial forecast and between designated percentages of the most recent previous forecast. The price of each shipment of solithromycin will be equal to the total number of kilograms in such shipment multiplied by the per-kilogram transfer price as set forth in the agreement. For the term of the agreement plus an additional five years or until the expiration of the patents identified in the agreement, FFFC is prohibited from supplying, selling or distributing solithromycin to, or enabling the manufacture of solithromycin by, any third party for any purpose. The Company is not precluded from developing one or more alternative or additional sources of solithromycin. The agreement’s initial term runs until December 2025. After the end of the initial term, and at the end of each year thereafter, the term will automatically extend for an additional year unless either party gives written notice to the other of its intent to terminate within a designated period of time prior to the expiration of the term, in which case the agreement will terminate at the end of such term. The parties may at any time terminate the agreement by mutual written consent. Each party has the right to terminate the agreement immediately if there is a product failure in Japan, the other party becomes involved in bankruptcy, insolvency or similar proceedings or materially breaches the agreement and such breach remains uncured for a period of time following notice of the breach. A violation by the Company of the minimum purchase obligation is considered a material breach. A product failure is not considered a material breach by the Company. The Company has the right to terminate the agreement upon written notice if there is a supply failure. The Company also may terminate in the event that FFFC cannot provide the Company with solithromycin for more than a designated period of time. Upon termination, any unfulfilled binding portion of the forecast must be delivered by FFFC and paid for by the Company. The Company also may elect to purchase the remaining inventory of FFFC’s solithromycin and any remaining raw materials. If FFFC terminates the agreement for a material breach by the Company and, prior to such termination, (i) FFFC has constructed a facility in Japan for the primary purpose of manufacturing API for the Company under the agreement and (ii) such facility is completed and fully operational and qualified for the manufacture of API for delivery thereunder, then, except to the extent otherwise agreed to by the parties, the Company will pay FFFC an amount equal to (a) the remaining book value of the facility less (b) the product of the number of kilograms of API ordered by the Company under the agreement prior to such termination times a designated dollar amount, provided that if the total direct costs incurred by FFFC in the construction of the facility, net of any tax credits, tax refunds, government subsidies, or similar financial, monetary, or in-kind benefits provided by any governmental agency or authority, do not equal or exceed a designated dollar amount, then the remaining book value will be reduced by a pro rata amount, based on ratios set forth in the agreement, and (z) no amount will be payable if the agreement terminates after December 31, 2025; provided, however, that if FFFC manufactures any product or performs any activities (other than the manufacture of API for the Company under the agreement) in, by, or using the facility prior to such termination and makes any profit thereby, the total amount of such profits will be subtracted from the total payment amount due from the Company to FFFC. Macrolide Pharmaceuticals, Inc. On January 29, 2016, Cempra Pharmaceuticals, Inc. entered into an Option and License Agreement with Macrolide Pharmaceuticals, Inc. (“MP”), pursuant to which MP granted the Company an exclusive option to license certain of MP’s patents and know-how involving macrolides, including specifically novel methods of synthesizing solithromycin (the “Compound”). Under the agreement, the Company will support research at MP focused on developing a novel, cost-competitive manufacturing approach to solithromycin. The option will run until the later to occur of (i) the earlier of (a) the date that the Company first obtains FDA approval for any product incorporating the Compound as an API, or (b) January 27, 2019, or (ii) the date that is six months after the earlier of (a) MP’s satisfaction of certain milestones, or (b) the Company’s termination of MP’s obligations under the evaluation program. Under the evaluation program called for in the agreement, MP will conduct research activities for the manufacture of the Compound, which activities the Company will evaluate to determine whether to exercise the option to license. Upon execution of the agreement, the Company paid MP a non-refundable, non-creditable initial license fee of $0.4 million. For conducting the evaluation program, the Company paid MP a non-refundable, non-creditable fee in the amount of $0.4 million. In June 2017, the Company entered into a Settlement Agreement with Macrolide Pharmaceuticals, Inc. to terminate the Option and License Agreement and paid the settlement payment of $0.2 million. |
Receivables
Receivables | 9 Months Ended |
Sep. 30, 2017 | |
Receivables [Abstract] | |
Receivables | 5. Receivables Receivables consist of amounts billed and amounts earned but unbilled under the Company’s contract with BARDA. At September 30, 2017, the Company’s receivables consisted primarily of earned but unbilled receivables under the BARDA agreement. |
Accrued Expenses
Accrued Expenses | 9 Months Ended |
Sep. 30, 2017 | |
Payables And Accruals [Abstract] | |
Accrued Expenses | 6. Accrued Expenses Accrued expenses are comprised of the following as of (in thousands): September 30, December 31, 2017 2016 Accrued severance $ 731 $ 1,999 Franchise tax 98 570 Deferred rent 81 85 Accrued interest 61 80 Lease liability 41 - Other accrued expenses 24 50 Accrued professional fees - 145 Total accrued expenses $ 1,036 $ 2,929 |
Long-Term Debt
Long-Term Debt | 9 Months Ended |
Sep. 30, 2017 | |
Debt Disclosure [Abstract] | |
Long-Term Debt | 7. Long-term Debt In July 2015, the Company entered into a Loan and Security Agreement (the “Loan and Security Agreement”) with Comerica Bank (“Comerica”). The Loan and Security Agreement provides that the Company may borrow up to $20.0 million in a term loan (the “Term Loan”) and, upon FDA approval of its New Drug Application for solithromycin, the Company may also borrow an aggregate amount equal to the lesser of (i) up to 75% of its eligible inventory and 80% of eligible accounts receivable or (ii) $10.0 million (the “Revolver”). After FDA approval of the Company’s New Drug Application for solithromycin, the Company may convert the Term Loan to the Revolver, in which event the Revolver would have a maximum amount available to the Company of $25.0 million. The Loan and Security Agreement specifies the criteria for determining eligible inventory and eligible accounts receivable and sets forth ongoing limitations and conditions precedent to the Company’s ability to borrow under the Revolver. The Company granted Comerica a security interest in substantially all of its personal property assets, excluding its intellectual property and its stock in its subsidiaries, to secure its outstanding obligations under the Loan and Security Agreement. The Company is also obligated to comply with various other customary covenants, including, among other things, restrictions on its ability to: dispose of assets, make acquisitions, be acquired, incur indebtedness, grant liens, make distributions to its stockholders, make investments, enter into certain transactions with affiliates, or pay down subordinated debt, subject to specified exceptions. Amounts borrowed under the Term Loan may be repaid and reborrowed at any time without penalty or premium. The Term Loan was interest-only through April 30, 2016, followed by an amortization period of 36 months of equal monthly payments of principal plus interest, beginning on May 1, 2016 and continuing on the same day of each month thereafter until paid in full. Any amounts borrowed under the Term Loan will bear interest at a floating interest rate equal to the 30 Day LIBOR rate plus 5.2%. Amounts available to be borrowed under the Revolver may also be repaid and reborrowed at any time without penalty or premium prior to December 31, 2017, at which time all advances under the Revolver shall be immediately due and payable in full. Any amounts borrowed under the Revolver will bear interest at the 30 Day LIBOR rate plus 4.2%. Once available, the Revolver is subject to an annual unused facility fee equal to 0.25%. Under the Loan and Security Agreement, the Company is subject to certain covenants including maintaining a minimum unrestricted cash balance of $15.0 million and continuing the development or commercially launching solithromycin. The Company was in compliance with all covenants at September 30, 2017. |
Commitments and Contingencies
Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2017 | |
Commitments And Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | 8. Commitments and Contingencies Legal Proceedings On November 4, 2016, a securities class action lawsuit was commenced in the United States District Court for the Middle District of North Carolina, Durham Division, naming the Company and certain of the Company’s officers as defendants, and alleging violations of the Securities Exchange Act of 1934 in connection with allegedly false and misleading statements made by the defendants between May 1, 2016 and November 1, 2016 (the “Class Period”). The plaintiff seeks to represent a class comprised of purchasers of the Company’s common stock during the Class Period and seeks damages, costs and expenses and such other relief as determined by the Court. Two substantially similar lawsuits were filed in the United States District Court, Middle District of North Carolina on November 22, 2016 and December 30, 2016, respectively, seeking to assert claims on behalf of all purchasers of the Company's common stock from July 7, 2015 through December 29, 2016, inclusive. Pursuant to the Private Securities Litigation Reform Act, on July 6, 2017, the court consolidated the three lawsuits into a single action and appointed a lead plaintiff and co-lead counsel in the consolidated case. On August 16, 2017, the plaintiffs in the case filed a consolidated amended complaint. On September 29, 2017, the defendants in the case filed a motion to dismiss the consolidated amended complaint. The Company believes it has meritorious defenses and intends to defend the lawsuits vigorously. It is possible that similar lawsuits may yet be filed in the same or other courts that name the same or additional defendants. On December 21, 2016, a shareholder derivative lawsuit was commenced in the North Carolina Durham County Superior Court, naming certain of the Company’s former and current officers and directors as defendants and the Company as a nominal defendant, and asserting claims for breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, and corporate waste. A substantially similar lawsuit was filed in the North Carolina Durham County Superior Court on February 16, 2017. The complaints are based on similar allegations as asserted in the putative securities class action described above, and seek unspecified damages and attorneys' fees. Both cases were served and transferred to the North Carolina Business Court as mandatory complex business cases. The Business Court has consolidated the two derivative cases into a single action and appointed lead counsel in the consolidated case. On July 6, 2017, the court entered an order staying the consolidated action pending resolution of the putative securities class action. On August 3, 2017, a shareholder derivative lawsuit was commenced in the Court of Chancery of the State of Delaware, naming certain of the Company's former and current officers and directors as defendants and the Company as nominal defendant, and asserting claims for breach of fiduciary duty, unjust enrichment, and corporate waste. The complaint is based on similar allegations as asserted in the putative securities class action described above, and seeks unspecified damages and attorneys' fees. On October 23, 2017, the defendants in the case filed a motion to dismiss the complaint. It is possible that similar lawsuits may yet be filed in the same or other courts that name the same or additional defendants. On September 15, 2017, a shareholder derivative lawsuit was commenced in the United State District Court for the Middle District of North Carolina, Durham Division, naming certain of the Company’s former and current officers and directors as defendants and the Company as nominal defendant, and asserting claims for breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, corporate waste, and alleged violation of Section 14(a) of the Exchange Act. The complaint is based on similar allegations as asserted in the putative securities class action described above, and seeks unspecified damages and attorneys’ fees. The complaint has not yet been served. It is possible that similar lawsuits may yet be filed in the same or other courts that name the same or additional defendants. On September 27, 2017, a putative class action complaint was filed against Cempra and the members of its board of directors on behalf of the public stockholders of Cempra in the United States District Court for the Middle District of North Carolina. The complaint alleges that the preliminary proxy statement issued in connection with the proposed merger between Cempra and Melinta Therapeutics, Inc. omitted material information in violation of Sections 14(a) and 20(a) of the Exchange Act, rendering the preliminary proxy statement false and misleading. Among other remedies, the action seeks to enjoin the merger unless and until additional disclosures are provided, damage, and attorneys’ fees. Cempra believes that the action is without merit and that no further disclosure is required to supplement the preliminary proxy statement under applicable laws. On October 6, 2017, a putative class action complaint was filed against Cempra and the members of its board of directors on behalf of the public stockholders of Cempra in the United States District Court for the Middle District of North Carolina. The complaint, filed after a definitive proxy statement was issued on October 5, 2017 in connected with the proposed merger between Cempra and Melinta Therapeutics, Inc, alleges that the preliminary proxy statement omitted material information in violation of Sections 14(a) and 20(a) of the Exchange Act, rendering the preliminary proxy statement false and misleading. Among other remedies, the action seeks to enjoin the merger unless and until additional disclosures are provided, damage and attorneys’ fees. Cempra believes that the action is without merit and that no further disclosure is required to supplement the preliminary proxy statement under applicable laws. Other than as described above, the Company is not a party to any legal proceedings and is not aware of any claims or actions pending or threatened against the Company. In the future, the Company might from time to time become involved in litigation relating to claims arising from its ordinary course of business. |
Shareholders' Equity
Shareholders' Equity | 9 Months Ended |
Sep. 30, 2017 | |
Equity [Abstract] | |
Shareholders' Equity | 9. Common Stock During January 2016, the Company completed a public offering of 4,166,667 shares of common stock, at a price of $24.00 per share, resulting in net proceeds to the Company of approximately $93.8 million after deducting underwriting discounts and expenses of approximately $6.2 million. In May 2016, the Company entered into an at-the-market (“ATM”) sales agreement (the “Sales Agreement”) with Cowen and Company, LLC (“Cowen”) under which the Company may, at its discretion, from time to time sell shares of its common stock, with a sales value of up to $150.0 million. The Company has provided Cowen with customary indemnification rights, and Cowen is entitled to a commission at a fixed commission rate of 3.0% of the gross proceeds per share sold. Sales of the shares under the Sales Agreement are to be made in transactions deemed to be “at the market offerings” as defined in Rule 415 under the Securities Act of 1933, as amended. The Company began the sale of ATM shares in May 2016 and through July 2016 the Company sold 4,140,307 shares of common stock under the Sales Agreement resulting in net proceeds of $75.1 million after deducting commissions and expenses of $2.3 million. The Company has not sold any shares under the ATM since July 2016. During the first nine months of 2017, the Company issued 116,376 shares of common stock at a weighted average exercise price of $2.23 per share upon the exercise of option grants. The following table presents common stock reserved for future issuance for the following equity instruments as of September 30, 2017: Warrants to purchase common stock 94,912 Outstanding stock options 4,120,220 Outstanding restricted stock units 1,015,000 Available for future grants under the 2011 Equity Incentive Plan 3,578,696 Total common stock reserved for future issuance 8,808,828 |
Stock Option Plans
Stock Option Plans | 9 Months Ended |
Sep. 30, 2017 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |
Stock Option Plans | 10. Stock Option Plans The Company adopted the 2006 Stock Plan (the “2006 Plan”) in January 2006. The 2006 Plan provided for the granting of incentive share options, nonqualified share options and restricted shares to Company employees, representatives and consultants. As of September 30, 2017, there were options for an aggregate of 341,854 shares issued and outstanding under the 2006 Plan. The Company’s board of directors and stockholders adopted the 2011 Equity Incentive Plan (the “2011 Plan”) in October 2011, which, as amended, authorizes the issuance of up to 8,697,451 shares under the 2011 Plan, and provides for an automatic annual increase in the number of shares of common stock reserved for issuance thereunder in the amount of 4% of the shares of common stock outstanding on December 31 of the preceding year. As of September 30, 2017, there were 3,578,696 options available under the 2011 Plan for future grant. Upon adoption of the 2011 Plan, the Company eliminated the authorization for any unissued shares previously reserved under the Company’s 2006 Plan. The stock awards previously issued under the 2006 Plan remain in effect in accordance with the terms of the 2006 Plan. The following table summarizes the Company’s 2006 and 2011 Plan stock option activity: Weighted Weighted Average Average Aggregate Number of Exercise Contractual Intrinsic Options Price Term (in years) Value (1) Outstanding - December 31, 2016 3,784,346 $ 16.26 Granted 1,921,750 3.08 Exercised (116,376 ) 2.23 Forfeited (1,074,516 ) 13.11 Expired (394,984 ) 16.64 Outstanding - September 30, 2017 4,120,220 11.30 6.90 $ 607,444 Exercisable - September 30, 2017 2,634,222 12.30 5.77 $ 434,044 Vested and expected to vest at September 30, 2017 (2) 4,011,877 $ 11.44 6.84 $ 591,929 (1) Intrinsic value is the excess of the fair value of the underlying common shares as of September 30, 2017 over the weighted-average exercise price. (2) The number of stock options expected to vest takes into account an estimate of expected forfeitures. The following table summarizes certain information about all stock options outstanding as of September 30, 2017: Options Outstanding Options Exercisable Exercise Price Number of Options Weighted Average Remaining Contractual Term (in years) Number of Options Weighted Average Remaining Contractual Term (in years) $2.09 - $3.15 1,682,841 7.75 661,739 5.31 $3.95 - $6.63 261,598 5.56 239,202 5.18 $6.64 - $12.38 659,093 5.62 630,839 5.47 $12.79 - $19.25 500,797 5.46 412,062 5.11 $22.77 - $34.49 996,141 7.37 676,629 7.06 $35.29 - $43.43 19,750 7.82 13,751 7.82 4,120,220 2,634,222 During the three-month periods ended September 30, 2017 and 2016, the Company recorded $1.5 million and $2.5 In 2016, the Company began issuing time-vested Restricted Stock Units (RSUs) from the 2011 Plan to certain employees, subject to continuous service with the Company at the vesting time. When vested, the RSU represents the right to be issued the number of shares of the Company’s common stock that is equal to the number of RSUs granted. A summary of the activity related to the Company’s RSUs is as follows: Number of Weighted Restricted Average Stock Units Grant-Date Outstanding Fair Value Balance - December 31, 2016 50,000 $ 7.70 Granted 1,283,000 3.12 Vested - - Forfeited (318,000 ) 3.09 Expired - - Balance - September 30, 2017 1,015,000 3.35 |
Income Taxes
Income Taxes | 9 Months Ended |
Sep. 30, 2017 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | 11. Income Taxes The Company estimates an annual effective tax rate of 0% for the year ending December 31, 2017 as the Company incurred losses for the nine-month period ended September 30, 2017 and is forecasting additional losses through the fourth quarter, resulting in an estimated net loss for both financial statement and tax purposes for the year ending December 31, 2017. Therefore, no federal or state income taxes are expected and none have been recorded at this time. Income taxes have been accounted for using the liability method in accordance with FASB ASC 740. Due to the Company’s history of losses since inception, there is not enough evidence at this time and it is not more likely than not that the Company will generate sufficient future income of a nature to utilize the benefits of its net deferred tax assets. Accordingly, the deferred tax assets have been reduced by a valuation allowance, since it has been determined that it is more likely than not that all of the deferred tax assets will not be realized. |
Net Loss Per Share
Net Loss Per Share | 9 Months Ended |
Sep. 30, 2017 | |
Earnings Per Share [Abstract] | |
Net Loss Per Share | 12. Net Loss Per Share Basic and diluted net loss per common share was determined by dividing net loss attributable to common shareholders by the weighted average common shares outstanding during the period. The Company’s potentially dilutive shares, which include warrants, common share options and restricted stock units, have not been included in the computation of diluted net loss per share for all periods as the result would be antidilutive. The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as they would be antidilutive: Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Warrants outstanding 94,912 94,912 94,912 94,912 Stock options outstanding 4,199,997 3,605,373 4,576,930 3,517,324 Restricted stock units outstanding 1,082,184 - 1,019,013 - 5,377,093 3,700,285 5,690,855 3,612,236 |
Basis of Presentation (Policies
Basis of Presentation (Policies) | 9 Months Ended |
Sep. 30, 2017 | |
Organization Consolidation And Presentation Of Financial Statements [Abstract] | |
Principles of Consolidation and Basis of Presentation | Principles of Consolidation and Basis of Presentation The accompanying consolidated financial statements include the accounts and results of operations of Cempra and its wholly owned subsidiaries. The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany balances and transactions have been eliminated in consolidation. |
Unaudited Interim Financial Data | Unaudited Interim Financial Data The accompanying interim consolidated financial statements are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the accompanying notes for the year ended December 31, 2016 contained in the Company’s Annual Report on Form 10-K. The unaudited interim consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary for the fair statement of the Company’s financial position as of September 30, 2017 and the results of operations and cash flows for the three and nine-months ended September 30, 2017 and 2016. The December 31, 2016 consolidated balance sheet included herein was derived from audited consolidated financial statements, but does not include all disclosures including notes required by U.S. GAAP for complete financial statements. |
Use of Estimates | Use of Estimates The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. |
Receivables | Receivables Receivables consist of amounts billed and amounts earned but unbilled under the Company’s contract with the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services (“BARDA”). Receivables under the BARDA contract are recorded as qualifying research activities are conducted and invoices from the Company’s vendors are received. Unbilled receivables are also recorded based upon work estimated to be complete for which the Company has not received vendor invoices. The Company carries its accounts receivable less an allowance for doubtful accounts. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance based on its history of collections and write-offs and the current status of all receivables. The Company does not accrue interest on trade receivables. If accounts become uncollectible, they will be written off through a charge to the allowance for doubtful accounts. The Company has not recorded an allowance for doubtful accounts as management believes all receivables are fully collectible. |
Research and Development Expenses | Research and Development Expenses Research and development (“R&D”) expenses include direct and indirect R&D costs. Direct R&D consists principally of external costs, such as fees paid to investigators, consultants, central laboratories and clinical research organizations, including costs incurred in connection with clinical trials, and related clinical trial fees and all employee-related expenses for those employees working in research and development functions, including stock-based compensation for R&D personnel. Indirect R&D costs include insurance or other indirect costs related to the Company’s research and development function to specific product candidates. R&D costs are expensed as incurred. Expenses paid but not yet incurred are recorded in prepaid expenses. The Company expenses purchases of pre-approval inventory as R&D until regulatory approval is received. |
Clinical Trial Accruals | Clinical Trial Accruals As part of the process of preparing financial statements, the Company is required to estimate its expenses resulting from its obligation under contracts with vendors and consultants and clinical site agreements in connection with conducting clinical trials. The Company’s objective is to reflect the appropriate clinical trial expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. The Company determines accrual estimates through discussion with applicable personnel and outside service providers as to the progress of trials or the services completed. During the course of a clinical trial, the Company adjusts its rate of clinical trial expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date in its financial statements based on facts and circumstances known at that time. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of status and timing of services performed relative to the actual status and timing of services performed may vary and may result in the Company reporting amounts that are too high or too low for any particular period. The Company’s clinical trial accrual is dependent upon the timely and accurate reporting of fee billings and passthrough expenses from contract research organizations and other third-party vendors as well as the timely processing of any change orders from the contract research organizations. |
Revenue Recognition | Revenue Recognition The Company’s revenue generally consists of research related revenue under federal contracts and licensing revenue related to non-refundable upfront fees, milestone payments and royalties earned under license agreements. Revenue is recognized when the following criteria are met: (1) persuasive evidence that an arrangement exists; (2) delivery of the products and/or services has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured. For arrangements that involve the delivery of more than one element, each product, service and/or right to use assets is evaluated to determine whether it qualifies as a separate unit of accounting. This determination is based on whether the deliverable has “stand-alone value” to the customer. The consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the relative selling prices of each deliverable. The consideration allocated to each unit of accounting is recognized as the related goods and services are delivered, limited to the consideration that is not contingent upon future deliverables. When an arrangement is accounted for as a single unit of accounting, the Company determines the period over which the performance obligations will be performed and revenue recognized. Milestone payments are recognized when earned, provided that (i) the milestone event is substantive; (ii) there is no ongoing performance obligation related to the achievement of the milestone earned; and (iii) it would result in additional payments. Milestone payments are considered substantive if all of the following conditions are met: the milestone payment is non-refundable; achievement of the milestone was not reasonably assured at the inception of the arrangement; substantive effort is involved to achieve the milestone; and the amount of the milestone appears reasonable in relation to the effort expended, the other milestones in the arrangement, and the related risk associated with the achievement of the milestone. Contingent-based payments the Company may receive under a license agreement will be recognized when received. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers. This new guidance clarifies the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP. The guidance outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes the most current revenue recognition guidance. This guidance, as amended by ASU 2015-14, is effective for fiscal years and interim periods within those years beginning after December 15, 2017, which is effective for the Company for the year ending December 31, 2018. In March 2016, the FASB issued ASU 2016-08, Revenue from Contracts with Customers: Principal versus Agent Considerations, which clarifies the implementation guidance on principal versus agent considerations. In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing, which clarifies an entity’s identification of its performance obligations in a contract. The update also clarifies the guidance regarding an entity’s evaluation of the nature of its promise to grant a license of intellectual property and whether or not that revenue is recognized over time or at a point in time. In May 2016, the FASB issued ASU 2016-12, Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients, which amends the guidance in the new revenue standard on collectability, non-cash consideration, presentation of sales tax, and transition. In December 2016, the FASB issued ASU 2016-20, Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers which increases shareholders’ awareness of the proposals and expedites improvements to Update 2014-09. In September 2017, the FASB issued ASU 2017-13, Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842), which allows certain public business entities to elect to use the non-public business entities effective dates to adopt new standards on revenue (ASC 606) and leases (ASC 842). The amendments are intended to address implementation issues that were raised by stakeholders and provide additional practical expedients to reduce the cost and complexity of applying the new revenue standard. These pronouncements have the same effective date as the new revenue standard. The Company has evaluated the contract research agreement with BARDA, and does not anticipate a material impact on the financial statements. The Company is currently evaluating the license agreement with Toyama to determine the impact that the implementation of this standard will have on the financial statements, if any. The Company plans to use the full retrospective method of adoption effective January 1, 2018. In February 2016, the FASB issued ASU 2016-02, Leases. The new guidance will increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. This guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements. In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation. The new guidance simplifies several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The Company adopted this guidance as of January 1, 2017. As of December 31, 2016, the Company has accumulated excess tax benefits from temporary differences in the amount and timing of stock compensation expense and the Company’s deductions on its income tax return from the award compensation that reduces the net operating loss deferred tax asset. The Company provided a full valuation allowance against its net deferred tax assets since it has been determined that it is more likely than not that all of the deferred tax assets will not be realized. Upon implementation of this standard, the stock compensation excess tax benefit will be eliminated, resulting in an increase to the net operating loss deferred tax asset, with an increase in the valuation allowance of the same. The implementation of this standard has no impact on the Company’s consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. This new guidance is effective for fiscal years beginning after December 15, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements. In January 2017, the FASB issued ASU 2017-01, Business Combinations: Clarifying the Definition of a Business which revises the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This new guidance is effective for fiscal years beginning after December 15, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements. In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation. This new guidance provides clarity and reduces both diversity and complexity to the terms or conditions of a share-based payment award. This new guidance is effective for fiscal years beginning after December 15, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements. |
Accrued Expenses (Tables)
Accrued Expenses (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Payables And Accruals [Abstract] | |
Accrued Expenses | Accrued expenses are comprised of the following as of (in thousands): September 30, December 31, 2017 2016 Accrued severance $ 731 $ 1,999 Franchise tax 98 570 Deferred rent 81 85 Accrued interest 61 80 Lease liability 41 - Other accrued expenses 24 50 Accrued professional fees - 145 Total accrued expenses $ 1,036 $ 2,929 |
Shareholders' Equity (Tables)
Shareholders' Equity (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Equity [Abstract] | |
Common Stock Reserved for Future Issuance | The following table presents common stock reserved for future issuance for the following equity instruments as of September 30, 2017: Warrants to purchase common stock 94,912 Outstanding stock options 4,120,220 Outstanding restricted stock units 1,015,000 Available for future grants under the 2011 Equity Incentive Plan 3,578,696 Total common stock reserved for future issuance 8,808,828 |
Stock Option Plans (Tables)
Stock Option Plans (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |
Stock Option Plans | The following table summarizes the Company’s 2006 and 2011 Plan stock option activity: Weighted Weighted Average Average Aggregate Number of Exercise Contractual Intrinsic Options Price Term (in years) Value (1) Outstanding - December 31, 2016 3,784,346 $ 16.26 Granted 1,921,750 3.08 Exercised (116,376 ) 2.23 Forfeited (1,074,516 ) 13.11 Expired (394,984 ) 16.64 Outstanding - September 30, 2017 4,120,220 11.30 6.90 $ 607,444 Exercisable - September 30, 2017 2,634,222 12.30 5.77 $ 434,044 Vested and expected to vest at September 30, 2017 (2) 4,011,877 $ 11.44 6.84 $ 591,929 (1) Intrinsic value is the excess of the fair value of the underlying common shares as of September 30, 2017 over the weighted-average exercise price. (2) The number of stock options expected to vest takes into account an estimate of expected forfeitures. |
Stock Options Outstanding | The following table summarizes certain information about all stock options outstanding as of September 30, 2017: Options Outstanding Options Exercisable Exercise Price Number of Options Weighted Average Remaining Contractual Term (in years) Number of Options Weighted Average Remaining Contractual Term (in years) $2.09 - $3.15 1,682,841 7.75 661,739 5.31 $3.95 - $6.63 261,598 5.56 239,202 5.18 $6.64 - $12.38 659,093 5.62 630,839 5.47 $12.79 - $19.25 500,797 5.46 412,062 5.11 $22.77 - $34.49 996,141 7.37 676,629 7.06 $35.29 - $43.43 19,750 7.82 13,751 7.82 4,120,220 2,634,222 |
Summary of RSUs Activity | A summary of the activity related to the Company’s RSUs is as follows: Number of Weighted Restricted Average Stock Units Grant-Date Outstanding Fair Value Balance - December 31, 2016 50,000 $ 7.70 Granted 1,283,000 3.12 Vested - - Forfeited (318,000 ) 3.09 Expired - - Balance - September 30, 2017 1,015,000 3.35 |
Net Loss Per Share (Tables)
Net Loss Per Share (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Earnings Per Share [Abstract] | |
Antidilutive Securities Excluded from Computation of Diluted Weighted Average Shares Outstanding | The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as they would be antidilutive: Three Months Ended September 30, Nine Months Ended September 30, 2017 2016 2017 2016 Warrants outstanding 94,912 94,912 94,912 94,912 Stock options outstanding 4,199,997 3,605,373 4,576,930 3,517,324 Restricted stock units outstanding 1,082,184 - 1,019,013 - 5,377,093 3,700,285 5,690,855 3,612,236 |
Description of Business - Addit
Description of Business - Additional Information (Details) | 1 Months Ended |
Aug. 31, 2017USD ($) | |
Melinta | |
Basis Of Presentation [Line Items] | |
Percentage of outstanding common stock | 52.00% |
Termination fee | $ 7,900,000 |
Maximum | |
Basis Of Presentation [Line Items] | |
Reimbursement of merger agreement expenses upon agreement termination | $ 2,000,000 |
Basis of Presentation - Additio
Basis of Presentation - Additional Information (Details) | Sep. 30, 2017USD ($) |
Organization Consolidation And Presentation Of Financial Statements [Abstract] | |
Allowance for doubtful accounts receivable recorded | $ 0 |
Fair Value of Financial Instr25
Fair Value of Financial Instruments - Additional Information (Details) - USD ($) | 9 Months Ended | |
Sep. 30, 2017 | Dec. 31, 2016 | |
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Transfers between levels of the fair value hierarchy | $ 0 | |
Term Loan | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Carrying value of notes | 10,300,000 | |
Recurring Basis | Money Market Funds | Quoted Prices in Active Markets for Identical Assets (Level 1) | ||
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] | ||
Assets classified as fair value of financial instruments | $ 173,000,000 | $ 228,500,000 |
Significant Agreements and Co26
Significant Agreements and Contracts - Additional Information (Details) | Oct. 31, 2016USD ($) | Jan. 29, 2016USD ($) | Aug. 31, 2014USD ($) | May 31, 2013USD ($) | Oct. 31, 2017 | Jun. 30, 2017USD ($) | Oct. 31, 2016USD ($) | Sep. 30, 2016USD ($) | Mar. 31, 2015USD ($) | Dec. 31, 2014USD ($) | Jul. 31, 2012USD ($) | Jul. 31, 2010USD ($) | Sep. 30, 2017USD ($)Segment | Sep. 30, 2016USD ($) | Jun. 30, 2012USD ($) | Sep. 30, 2017USD ($)ProductSegmentDeliverablesshares | Sep. 30, 2016USD ($) | Sep. 30, 2017USD ($)Segment | Dec. 31, 2016USD ($) | Feb. 29, 2016USD ($) |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||||||
Contract research | $ 1,717,000 | $ 3,972,000 | $ 7,449,000 | $ 10,071,000 | ||||||||||||||||
Deferred revenue | 16,987,000 | $ 16,987,000 | $ 16,987,000 | $ 16,987,000 | ||||||||||||||||
Optimer Pharmaceuticals Inc | Collaborative Arrangement | ||||||||||||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||||||
Common shares issued to Optimer in exchange for license | shares | 125,646 | |||||||||||||||||||
Fair value of common shares issued to Optimer | $ 200,000 | |||||||||||||||||||
Milestone payment paid | $ 1,000,000 | $ 500,000 | ||||||||||||||||||
Milestone payment owed upon FDA approval | 9,500,000 | 9,500,000 | 9,500,000 | |||||||||||||||||
Aggregate amount of milestone payment | 27,500,000 | $ 27,500,000 | 27,500,000 | |||||||||||||||||
Number of products required to be developed through FDA approval | Product | 4 | |||||||||||||||||||
Royalty payment based on annual net sales description | The Company will also pay tiered mid-single-digit royalties based on the amount of annual net sales of its approved products. | |||||||||||||||||||
The Scripps Research Institute | ||||||||||||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||||||
Milestone payment paid | $ 200,000 | |||||||||||||||||||
Royalty payment based on annual net sales description | Under the terms of the agreement, the Company must pay TSRI low single-digit percentage royalties on the net sales of the products covered by the TSRI patents for the life of the TSRI patents, a low single-digit percentage of non-royalty sublicensing revenue received with respect to countries in the nonexclusive territory and a mid-single-digit percentage of sublicensing revenue received with respect to countries in the exclusive territory, with the sublicensing revenue royalty in the exclusive territory and the sales royalties subject to certain reductions under certain circumstances. | |||||||||||||||||||
Non refundable license issue fee | $ 400,000 | |||||||||||||||||||
Eligible milestone payment | $ 1,100,000 | |||||||||||||||||||
The Scripps Research Institute | First Three Years | ||||||||||||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||||||
Annual maintenance fees | 50,000 | |||||||||||||||||||
The Scripps Research Institute | Fourth Through Six Years | ||||||||||||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||||||
Annual maintenance fees | 85,000 | |||||||||||||||||||
Biomedical Advanced Research and Development Authority | ||||||||||||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||||||
Value of cost plus fixed fee development contract with base performance segment | $ 18,700,000 | $ 18,700,000 | $ 18,700,000 | |||||||||||||||||
Number of option work segments | Segment | 4 | 4 | 4 | |||||||||||||||||
Cumulative value of cost plus fixed fee development contract with base performance segment of four option work segments | $ 68,200,000 | $ 68,200,000 | $ 68,200,000 | |||||||||||||||||
Number of options under cost plus fixed fee arrangements | Segment | 3 | |||||||||||||||||||
Number of options under cost sharing arrangement without fixed fee | Segment | 1 | |||||||||||||||||||
Estimated period of performance for the base performance segment | 2018-05 | |||||||||||||||||||
Aggregate milestone payments receivable under license agreement | 2013-05 | |||||||||||||||||||
Estimated period of performance for the base performance segment ending date | 2016-02 | |||||||||||||||||||
Contract research | 46,700,000 | |||||||||||||||||||
Reimbursement of expenses or return of funds for noncompliance | 0 | |||||||||||||||||||
Biomedical Advanced Research and Development Authority | Second Option Work | ||||||||||||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||||||
Value of cost plus fixed fee development contract with base performance segment | 16,000,000 | $ 16,000,000 | 16,000,000 | |||||||||||||||||
Aggregate milestone payments receivable under license agreement | 2014-11 | |||||||||||||||||||
Estimated period of performance for the base performance segment ending date | 2018-09 | |||||||||||||||||||
Biomedical Advanced Research and Development Authority | Second Option Work | Subsequent Event | ||||||||||||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||||||
Estimated period of performance for the base performance segment ending date | 2017-10 | |||||||||||||||||||
Biomedical Advanced Research and Development Authority | Third Option Work | ||||||||||||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||||||
Value of cost plus fixed fee development contract with base performance segment | 33,500,000 | $ 33,500,000 | 33,500,000 | $ 25,500,000 | ||||||||||||||||
Increase in value of cost plus fixed fee development contract with base performance segment | $ 8,000,000 | |||||||||||||||||||
Toyama Chemical | ||||||||||||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||||||
Contract research | 6,100,000 | |||||||||||||||||||
Deferred revenue | $ 10,000,000 | $ 17,000,000 | $ 17,000,000 | $ 17,000,000 | ||||||||||||||||
Aggregate milestone payments | 60,000,000 | |||||||||||||||||||
Milestone payment amount received | $ 10,000,000 | $ 10,000,000 | ||||||||||||||||||
Milestone payment recognized as revenue | $ 4,300,000 | $ 4,300,000 | $ 4,300,000 | $ 10,000,000 | ||||||||||||||||
Number of deliverables under license agreement | Deliverables | 6 | |||||||||||||||||||
Supply agreement date | May 31, 2013 | |||||||||||||||||||
FUJIFILM Finechemicals Co., Ltd. | ||||||||||||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||||||
Manufacturing and supply agreement date | Jan. 31, 2016 | |||||||||||||||||||
Prohibition term | For the term of the agreement plus an additional five years or until the expiration of the patents identified in the agreement, FFFC is prohibited from supplying, selling or distributing solithromycin to, or enabling the manufacture of solithromycin by, any third party for any purpose. The Company is not precluded from developing one or more alternative or additional sources of solithromycin. | |||||||||||||||||||
Aggregate initial term of agreement | Dec. 31, 2025 | |||||||||||||||||||
Macrolide Pharmaceuticals, Inc. | Option and License Agreement | ||||||||||||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||||||
Agreement description | The option will run until the later to occur of (i) the earlier of (a) the date that the Company first obtains FDA approval for any product incorporating the Compound as an API, or (b) January 27, 2019, or (ii) the date that is six months after the earlier of (a) MP’s satisfaction of certain milestones, or (b) the Company’s termination of MP’s obligations under the evaluation program. | |||||||||||||||||||
Non-refundable non-creditable initial license fee | $ 400,000 | |||||||||||||||||||
Non-refundable non-creditable fee | $ 400,000 | |||||||||||||||||||
Macrolide Pharmaceuticals, Inc. | Settlement Agreement | ||||||||||||||||||||
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||||||||||||||||||||
Settlement payment for termination of option and license agreement | $ 200,000 |
Accrued Expenses - Accrued Expe
Accrued Expenses - Accrued Expenses (Details) - USD ($) $ in Thousands | Sep. 30, 2017 | Dec. 31, 2016 |
Accrued expenses | ||
Accrued severance | $ 731 | $ 1,999 |
Franchise tax | 98 | 570 |
Deferred rent | 81 | 85 |
Accrued interest | 61 | 80 |
Lease liability | 41 | |
Other accrued expenses | 24 | 50 |
Accrued professional fees | 145 | |
Total accrued expenses | $ 1,036 | $ 2,929 |
Long-Term Debt - Additional Inf
Long-Term Debt - Additional Information (Details) - Loan and Security Agreement - USD ($) | 1 Months Ended | 9 Months Ended |
Jul. 31, 2015 | Sep. 30, 2017 | |
Debt Instrument [Line Items] | ||
Minimum unrestricted cash balance requirement | $ 15,000,000 | |
Term Loan | ||
Debt Instrument [Line Items] | ||
Loan and security agreement | $ 20,000,000 | |
Eligible inventory percentage for additional borrowings | 75.00% | |
Eligible accounts receivable for additional borrowings | 80.00% | |
End date of interest-only payment | Apr. 30, 2016 | |
Amortization period of principal and interest payments | 36 months | |
Description of variable rate basis | 30 Day LIBOR | |
Beginning date for principal plus interest payment | May 1, 2016 | |
Term Loan | LIBOR | ||
Debt Instrument [Line Items] | ||
Basis spread on variable rate | 5.20% | |
Revolver | ||
Debt Instrument [Line Items] | ||
Loan and security agreement | $ 10,000,000 | |
Maximum borrowing capacity if term loans are converted | $ 25,000,000 | |
Description of variable rate basis | 30 Day LIBOR | |
Last date for repayment and reborrowed without penalty or premium | Dec. 31, 2017 | |
Annual unused facility fee percentage | 0.25% | |
Revolver | LIBOR | ||
Debt Instrument [Line Items] | ||
Basis spread on variable rate | 4.20% |
Commitments and Contingencies -
Commitments and Contingencies - Additional Information (Details) - Lawsuit | Jul. 06, 2017 | Sep. 30, 2017 |
Securities Class Action | ||
Loss Contingencies [Line Items] | ||
Lawsuit commencement date | Nov. 4, 2016 | |
Lawsuit action domicile | United States District Court for the Middle District of North Carolina, Durham Division | |
Name of defendant | officers | |
Allegations in the class period | between May 1, 2016 and November 1, 2016 | |
Loss contingency, actions determined by court | The plaintiff seeks to represent a class comprised of purchasers of the Company’s common stock during the Class Period and seeks damages, costs and expenses and such other relief as determined by the Court | |
Number of lawsuits filed | 2 | |
Lawsuit filing date | November 22, 2016 and December 30, 2016 | |
Lawsuit description | Two substantially similar lawsuits were filed in the United States District Court, Middle District of North Carolina on November 22, 2016 and December 30, 2016, respectively, seeking to assert claims on behalf of all purchasers of the Company's common stock from July 7, 2015 through December 29, 2016, inclusive. | |
Number of lawsuits consolidated | 3 | |
Shareholder Derivative | ||
Loss Contingencies [Line Items] | ||
Lawsuit commencement date | Dec. 21, 2016 | |
Lawsuit action domicile | North Carolina Durham County Superior Court | |
Name of defendant | officers and directors | |
Lawsuit filing date | February 16, 2017 | |
Number of lawsuits consolidated | 2 | |
Shareholder Derivative | Pending Litigation | ||
Loss Contingencies [Line Items] | ||
Lawsuit commencement date | Aug. 3, 2017 | |
Lawsuit action domicile | Court of Chancery of the State of Delaware | |
Name of defendant | officers and directors | |
Lawsuit filing date | October 23, 2017 | |
Legal Proceedings Case Four | ||
Loss Contingencies [Line Items] | ||
Lawsuit commencement date | Sep. 15, 2017 | |
Lawsuit action domicile | United State District Court for the Middle District of North Carolina, Durham Division | |
Name of defendant | officers and directors | |
Legal Proceedings Case Five | ||
Loss Contingencies [Line Items] | ||
Lawsuit action domicile | United States District Court for the Middle District of North Carolina | |
Lawsuit filing date | September 27, 2017 | |
Legal Proceedings Case Six | ||
Loss Contingencies [Line Items] | ||
Lawsuit action domicile | United States District Court for the Middle District of North Carolina | |
Lawsuit filing date | October 6, 2017 |
Shareholders' Equity - Addition
Shareholders' Equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||
Jan. 31, 2016 | Jul. 31, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | Jun. 30, 2017 | Dec. 31, 2016 | May 31, 2016 | |
Shareholders' Equity (Deficit) (Textual) [Abstract] | |||||||
Common stock sale value | $ 53 | $ 52 | |||||
Proceeds from issuance of common stock, net of underwriting discounts | $ 169,112 | ||||||
Issuance of common shares upon exercise of options, shares | 116,376 | ||||||
Weighted average exercise price of common stock | $ 2.23 | ||||||
Cowen And Company Limited Liability Company | At The Market Sales Agreement | |||||||
Shareholders' Equity (Deficit) (Textual) [Abstract] | |||||||
Common stock sale value | $ 150,000 | ||||||
Commission on sale of common stock under the ATM | 3.00% | ||||||
Common Stock | |||||||
Shareholders' Equity (Deficit) (Textual) [Abstract] | |||||||
Number of common stocks issued through public offering | 4,166,667 | 4,140,307 | 0 | ||||
Common share price | $ 24 | ||||||
Proceeds from issuance of common stock, net of underwriting discounts and offering costs | $ 93,800 | ||||||
Underwriting discounts and commissions, and expenses | $ 6,200 | ||||||
Proceeds from issuance of common stock, net of underwriting discounts | $ 75,100 | ||||||
Commissions and expenses | $ 2,300 | ||||||
Issuance of common shares upon exercise of options, shares | 116,376 | ||||||
Weighted average exercise price of common stock | $ 2.23 |
Shareholders' Equity - Common S
Shareholders' Equity - Common Stock Reserved for Future Issuance (Details) | Sep. 30, 2017shares |
Class Of Stock [Line Items] | |
Common stock reserved for future issuance | 8,808,828 |
Warrants to Purchase Common Stock | |
Class Of Stock [Line Items] | |
Common stock reserved for future issuance | 94,912 |
Outstanding Stock Options | |
Class Of Stock [Line Items] | |
Common stock reserved for future issuance | 4,120,220 |
Outstanding Restricted Stock Units | |
Class Of Stock [Line Items] | |
Common stock reserved for future issuance | 1,015,000 |
Options Available For Future Grants | 2011 Equity Incentive Plan | |
Class Of Stock [Line Items] | |
Common stock reserved for future issuance | 3,578,696 |
Stock Option Plans - Additional
Stock Option Plans - Additional Information (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended | ||||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | Dec. 31, 2016 | Oct. 31, 2011 | |
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||
Options for shares issued and outstanding | 4,120,220 | 4,120,220 | 3,784,346 | |||
Share-based compensation | $ 1.5 | $ 2.5 | $ 5.5 | $ 7.5 | ||
Unrecognized compensation cost | $ 5.6 | $ 5.6 | ||||
Expected weighted average recognition period, Unvested shares | 2 years 5 months 5 days | |||||
2006 Stock Plan | ||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||
Options for shares issued and outstanding | 341,854 | 341,854 | ||||
2011 Equity Incentive Plan | ||||||
Share Based Compensation Arrangement By Share Based Payment Award [Line Items] | ||||||
Maximum number of shares authorized for future issuances | 8,697,451 | |||||
Options shares available under the 2011 Plan | 3,578,696 | 3,578,696 | ||||
Percent of annual increase in share reserved for future issuance | 4.00% |
Stock Option Plans - Stock Opti
Stock Option Plans - Stock Option Plans (Details) | 9 Months Ended |
Sep. 30, 2017USD ($)$ / sharesshares | |
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] | |
Number of Options, Outstanding - December 31, 2016 | shares | 3,784,346 |
Number of Options, Granted | shares | 1,921,750 |
Number of Options, Exercised | shares | (116,376) |
Number of Options, Forfeited | shares | (1,074,516) |
Number of Options, Expired | shares | (394,984) |
Number of Options, Outstanding - September 30, 2017 | shares | 4,120,220 |
Number of Options, Exercisable - September, 2017 | shares | 2,634,222 |
Number of Options, Vested and expected to vest at September 30, 2017 | shares | 4,011,877 |
Weighted Average Exercise Price, Outstanding - December 31, 2016 | $ / shares | $ 16.26 |
Weighted Average Exercise Price, Granted | $ / shares | 3.08 |
Weighted Average Exercise Price, Exercised | $ / shares | 2.23 |
Weighted Average Exercise Price, Forfeited | $ / shares | 13.11 |
Weighted Average Exercise Price, Expired | $ / shares | 16.64 |
Weighted Average Exercise Price, Outstanding - September, 2017 | $ / shares | 11.30 |
Weighted Average Exercise Price, Exercisable - September 30, 2017 | $ / shares | 12.30 |
Weighted Average Exercise Price, Vested and expected to vest at September 30, 2017 | $ / shares | $ 11.44 |
Weighted Average Contractual Term (in years), Outstanding - September 30, 2017 | 6 years 10 months 24 days |
Weighted Average Contractual Term (in years), Exercisable - September 30, 2017 | 5 years 9 months 7 days |
Weighted Average Contractual Term (in years), Vested and expected to vest at September 30, 2017 | 6 years 10 months 2 days |
Aggregate Intrinsic Value, Outstanding - September 30, 2017 | $ | $ 607,444 |
Aggregate Intrinsic Value, Exercisable - September 30, 2017 | $ | 434,044 |
Aggregate Intrinsic Value, Vested and expected to vest at September 30, 2017 | $ | $ 591,929 |
Stock Option Plans - Stock Op34
Stock Option Plans - Stock Options Outstanding (Details) - $ / shares | 9 Months Ended | |
Sep. 30, 2017 | Dec. 31, 2016 | |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Number of Options Outstanding | 4,120,220 | 3,784,346 |
Number of Options, Exercisable | 2,634,222 | |
Exercise Price $2.09 - $3.15 | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise price range lower range limit | $ 2.09 | |
Exercise price range upper range limit | $ 3.15 | |
Number of Options Outstanding | 1,682,841 | |
Weighted Average Remaining Contractual Term (in years), Outstanding | 7 years 9 months | |
Number of Options, Exercisable | 661,739 | |
Weighted Average Remaining Contractual Term (in years), Exercisable | 5 years 3 months 21 days | |
Exercise Price $3.95 - $6.63 | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise price range lower range limit | $ 3.95 | |
Exercise price range upper range limit | $ 6.63 | |
Number of Options Outstanding | 261,598 | |
Weighted Average Remaining Contractual Term (in years), Outstanding | 5 years 6 months 22 days | |
Number of Options, Exercisable | 239,202 | |
Weighted Average Remaining Contractual Term (in years), Exercisable | 5 years 2 months 5 days | |
Exercise Price $6.64 - $12.38 | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise price range lower range limit | $ 6.64 | |
Exercise price range upper range limit | $ 12.38 | |
Number of Options Outstanding | 659,093 | |
Weighted Average Remaining Contractual Term (in years), Outstanding | 5 years 7 months 14 days | |
Number of Options, Exercisable | 630,839 | |
Weighted Average Remaining Contractual Term (in years), Exercisable | 5 years 5 months 20 days | |
Exercise Price $12.79 - $19.25 | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise price range lower range limit | $ 12.79 | |
Exercise price range upper range limit | $ 19.25 | |
Number of Options Outstanding | 500,797 | |
Weighted Average Remaining Contractual Term (in years), Outstanding | 5 years 5 months 16 days | |
Number of Options, Exercisable | 412,062 | |
Weighted Average Remaining Contractual Term (in years), Exercisable | 5 years 1 month 9 days | |
Exercise Price $22.77 - $34.49 | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise price range lower range limit | $ 22.77 | |
Exercise price range upper range limit | $ 34.49 | |
Number of Options Outstanding | 996,141 | |
Weighted Average Remaining Contractual Term (in years), Outstanding | 7 years 4 months 14 days | |
Number of Options, Exercisable | 676,629 | |
Weighted Average Remaining Contractual Term (in years), Exercisable | 7 years 22 days | |
Exercise Price $35.29 - $43.43 | ||
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items] | ||
Exercise price range lower range limit | $ 35.29 | |
Exercise price range upper range limit | $ 43.43 | |
Number of Options Outstanding | 19,750 | |
Weighted Average Remaining Contractual Term (in years), Outstanding | 7 years 9 months 25 days | |
Number of Options, Exercisable | 13,751 | |
Weighted Average Remaining Contractual Term (in years), Exercisable | 7 years 9 months 25 days |
Stock Option Plans - Summary of
Stock Option Plans - Summary of RSUs Activity (Details) - Restricted Stock Units - 2011 Equity Incentive Plan | 9 Months Ended |
Sep. 30, 2017$ / sharesshares | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] | |
Number of Restricted Stock Units Outstanding, Balance - December 31, 2016 | shares | 50,000 |
Number of Restricted Stock Units Outstanding, Granted | shares | 1,283,000 |
Number of Restricted Stock Units Outstanding, Forfeited | shares | (318,000) |
Number of Restricted Stock Units Outstanding, Balance - September 30, 2017 | shares | 1,015,000 |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] | |
Weighted Average Grant-Date Fair Value, Balance - December 31, 2016 | $ / shares | $ 7.70 |
Weighted Average Grant-Date Fair Value, Granted | $ / shares | 3.12 |
Weighted Average Grant-Date Fair Value, Forfeited | $ / shares | 3.09 |
Weighted Average Grant-Date Fair Value, Balance - September 30, 2017 | $ / shares | $ 3.35 |
Income Taxes - Additional Infor
Income Taxes - Additional Information (Details) - USD ($) | 9 Months Ended | 12 Months Ended |
Sep. 30, 2017 | Dec. 31, 2017 | |
U.S. Federal or State Income Tax | ||
Income Tax Contingency [Line Items] | ||
Income tax expense | $ 0 | |
Scenario Forecast | ||
Income Tax Contingency [Line Items] | ||
Effective tax rate | 0.00% |
Net Loss Per Share - Antidiluti
Net Loss Per Share - Antidilutive Securities Excluded from Computation of Diluted Weighted Average Shares Outstanding (Details) - shares | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | |
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from computation of diluted weighted average shares outstanding | 5,377,093 | 3,700,285 | 5,690,855 | 3,612,236 |
Warrants Outstanding | ||||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from computation of diluted weighted average shares outstanding | 94,912 | 94,912 | 94,912 | 94,912 |
Stock Options Outstanding | ||||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from computation of diluted weighted average shares outstanding | 4,199,997 | 3,605,373 | 4,576,930 | 3,517,324 |
Outstanding Restricted Stock Units | ||||
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from computation of diluted weighted average shares outstanding | 1,082,184 | 1,019,013 |